Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Fgastroenterology%2Fvedolizumab-and-anti-tnf-therapies-a-real-world-comparison%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Conference+Report+Article%7CGastroenterology%7CECCO+2020%7CHead-to-Head+Comparison+of+Treatments): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Vedolizumab and anti-TNF therapies: a real-world comparison - Medical Conferences

Home > Gastroenterology > ECCO 2020 > Head-to-Head Comparison of Treatments > Vedolizumab and anti-TNF therapies: a real-world comparison

Vedolizumab and anti-TNF therapies: a real-world comparison

Presented By
Dr G. Mantzaris , Evangelismos Hospital, Greece

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2020
Trial
EVOLVE
In a real-world comparison of vedolizumab and anti-TNF therapies in biologic-naïve ulcerative colitis (UC) patients, vedolizumab was associated with higher persistence, lower likelihood of exacerbations and a better safety profile [1]. However, sample size limitations necessitate further study.

The EVOLVE study is one of the first to compare a biological with anti-TNF as early treatment of UC. It was a real-world, multi-country, retrospective chart review study in Canada, Greece, and the USA. The clinical effectiveness and safety of vedolizumab or an anti-TNF (adalimumab, infliximab, or golimumab) as a first-line biologic initiated within 2 years after diagnosis were assessed. A total of 176 UC patients from 37 sites were included in the analysis: 86 using vedolizumab and 90 using anti-TNF. The mean age in both groups was 41.4 and 36.8 years, respectively. The proportion of men was 58.1% and 56.7%, respectively.

At 12 months, 72.9% and 58.1% still used vedolizumab and anti-TNF respectively (P=0.03). There were no differences in clinical response, clinical remission, or mucosal healing. However, vedolizumab users had a significantly lower risk of UC exacerbations (HR 0.47; 95% CI 0.32–0.69) and serious adverse events (HR 0.37; 95% CI: 0.19–0.72). The authors concluded that, based on these findings, early treatment with vedolizumab may improve long-term clinical outcomes.


    1. Mantzaris G, et al. ECCO-IBD 2020, DOP55.




Posted on